Dr. Dicker on the Impact of Genetic Testing for Prostate Cancer

Adam P. Dicker, MD, PhD
Published: Tuesday, Apr 04, 2017



Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Genetic testing has already effected how patients with metastatic prostate cancer are treated, Dicker states.

The standard of care at Thomas Jefferson University, is to do a biopsy of the metastatic site. Then, next-generation sequencing is used and if results determine an alteration in a DNA damaged pathway, the patient may receive a PARP inhibitor or platinum-based therapy, explains Dicker.
 


Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Genetic testing has already effected how patients with metastatic prostate cancer are treated, Dicker states.

The standard of care at Thomas Jefferson University, is to do a biopsy of the metastatic site. Then, next-generation sequencing is used and if results determine an alteration in a DNA damaged pathway, the patient may receive a PARP inhibitor or platinum-based therapy, explains Dicker.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x